The estimated Net Worth of Carl Le Bel is at least $2.24 Milione dollars as of 5 July 2022. Carl Bel owns over 15,000 units of Frequency Therapeutics Inc stock worth over $9,229 and over the last 10 years he sold FREQ stock worth over $14,986. In addition, he makes $2,217,220 as Chief Development Officer at Frequency Therapeutics Inc.
Sign up
Carl LeBel FREQ stock SEC Form 4 insiders trading
Carl has made over 9 trades of the Frequency Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 15,000 units of FREQ stock worth $4,500 on 5 July 2022.
The largest trade he's ever made was exercising 21,250 units of Frequency Therapeutics Inc stock on 6 September 2016 worth over $117,725. On average, Carl trades about 6,811 units every 130 days since 2014. As of 5 July 2022 he still owns at least 30,764 units of Frequency Therapeutics Inc stock.
You can see the complete history of Carl Bel stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Carl LeBel biography
Dr. Carl P. LeBel Ph.D. serves as Chief Development Officer of the Company. serves as Chief Development Officer of the Company. serves as Chief Development Officer of the Company. Dr. LeBel founded LeBel Consulting, LLC, a biopharmaceutical consulting company. Prior to joining our company, from February 2009 until November 2016, Dr. LeBel served as the Chief Scientific Officer of Otonomy, Inc., or Otonomy, a biopharmaceutical company, where he was responsible for all research and development activities. From 2008 to 2009, he served as the President and Chief Executive Officer of Akesis Pharmaceuticals, Inc., or Akesis, a virtual metabolic disorders company. Prior to Akesis, Dr. LeBel served as an Executive Director in a variety of research and development management positions for Amgen, Inc., or Amgen, a biopharmaceutical Dr. LeBel founded LeBel Consulting, LLC, a biopharmaceutical consulting company. Prior to joining our company, from February 2009 until November 2016, Dr. LeBel served as the Chief Scientific Officer of Otonomy, Inc., or Otonomy, a biopharmaceutical company, where he was responsible for all research and development activities. From 2008 to 2009, he served as the President and Chief Executive Officer of Akesis Pharmaceuticals, Inc., or Akesis, a virtual metabolic disorders company. Prior to Akesis, Dr. LeBel served as an Executive Director in a variety of research and development management positions for Amgen, Inc., or Amgen, a biopharmaceutical
What is the salary of Carl LeBel?
As the Chief Development Officer of Frequency Therapeutics Inc, the total compensation of Carl LeBel at Frequency Therapeutics Inc is $2,217,220. There are 2 executives at Frequency Therapeutics Inc getting paid more, with David Lucchino having the highest compensation of $7,364,600.
How old is Carl LeBel?
Carl LeBel is 61, he's been the Chief Development Officer of Frequency Therapeutics Inc since 2018. There are 5 older and 12 younger executives at Frequency Therapeutics Inc. The oldest executive at Frequency Therapeutics Inc is Timothy Barberich, 72, who is the Independent Director.
What's Carl LeBel's mailing address?
Carl's mailing address filed with the SEC is C/O FREQUENCY THERAPEUTICS, INC., 75 HAYDEN AVE, SUITE 300, LEXINGTON, MA, 02421.
Insiders trading at Frequency Therapeutics Inc
Over the last 5 years, insiders at Frequency Therapeutics Inc have traded over $11,017,122 worth of Frequency Therapeutics Inc stock and bought 369,233 units worth $5,339,982 . The most active insiders traders include Joel S Marcus, Robert Langer e Marc A Cohen. On average, Frequency Therapeutics Inc executives and independent directors trade stock every 11 days with the average trade being worth of $3,858. The most recent stock trade was executed by Richard J. Mitrano on 18 August 2023, trading 464 units of FREQ stock currently worth $269.
What does Frequency Therapeutics Inc do?
frequency therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. through the controlled activation of progenitor cells, frequency enables disease modification without the complexity of genetic engineering. our lead program re-creates sensory cells in the inner ear to treat chronic noise induced hearing loss, which affects over 30 million people in the u.s. alone.
What does Frequency Therapeutics Inc's logo look like?
Complete history of Carl Bel stock trades at Otonomy Inc e Frequency Therapeutics Inc
Frequency Therapeutics Inc executives and stock owners
Frequency Therapeutics Inc executives and other stock owners filed with the SEC include:
-
David Lucchino,
President, Chief Executive Officer, Co-Founder, Director -
Christopher Loose,
Co-Founder, Chief Scientific Officer -
Carl LeBel,
Chief Development Officer -
David L. Lucchino,
Co-Founder, Pres, CEO & Director -
Wendy S. Arnold,
Chief People Officer -
Peter P. Pfreundschuh,
Chief Financial Officer -
Robert Langer,
Independent Director -
Marc Cohen,
Lead Independent Chairman of the Board Director -
Joel Marcus,
Independent Director -
Michael Huang,
Independent Director -
Timothy Barberich,
Independent Director -
Carlo Tanzi,
IR Contact Officer -
Cynthia Feldmann,
Independent Director -
Dana Hilt,
Chief Medical Officer -
Ajay Rai,
Vice President - Business Development -
Richard Mitrano,
Vice President of Finance and Operations -
Wendy Arnold,
Chief People Officer -
William Mclean,
Co-Founder, Vice President - Biology and Regenerative Medicine -
Dr. Carl P. LeBel,
Chief Devel. Officer -
Dr. Christopher R. Loose,
CoÂ-Founder & Chief Scientific Officer -
Dr. William W. Chin M.D.,
Sr. VP of Translational Medicine -
Dr. Dana C. Hilt,
Chief Medical Officer -
Dr. Jeff Hrkach,
Sr. VP of Technology Devel. -
Richard J. Mitrano,
VP of Fin. & Operations -
William J. McLean Ph.D.,
Co-founder & Sr. VP of Hearing Biology and Translational Research -
Quentin Mc Cubbin,
Chief Manufacturing Officer -
James E Deerfield Mgmt L.P....,
-
Peter P. Pfreundschuh,
Chief Financial Officer -
Michael Bookman,
General Counsel and Secretary